The U.S. government has invested more than $3 billion to stockpile medical countermeasures against bioterrorism since 2001. The largest single acquisition has been of a first-generation anthrax vaccine that was marketed before 2001. Stockpile quantities are sufficient to protect first-responders and a small portion of the